ロード中...
A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4–6 μg/kg) in patients with major depressive disorder
BACKGROUND: Depressive disorders are a leading cause of disability, but current behavioural and pharmacological therapies have a slow onset of response, typically taking several weeks before achieving efficacy. Prior studies using triplicate intravenous scopolamine infusions have been shown to reduc...
保存先:
| 出版年: | Trials |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7011244/ https://ncbi.nlm.nih.gov/pubmed/32041658 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-020-4089-6 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|